Dyadic International, Inc. has recently reported significant milestone payments from its collaborations with Proliant Health & Biologicals in life sciences and Inzymes ApS in food and nutrition, reflecting a robust business transformation and commercial advancement. This progress underscores Dyadic’s strategic shift towards becoming a commercially focused entity, as highlighted by Joe Hazelton, President and COO of Dyadic Applied BioSolutions.
In the third quarter, Dyadic’s partnerships have yielded notable achievements, particularly in recombinant protein production. The company reached a $500,000 milestone in its partnership with Proliant for recombinant human albumin, with commercial launch anticipated in late 2025. Additionally, advancements in recombinant transferrin and DNase I production are set to meet growing demands in various markets, including diagnostics and biopharma.
Moreover, Dyadic’s collaboration with Inzymes has led to a $250,000 milestone payment, signaling progress in the development of non-animal dairy enzymes. As these initiatives unfold, Dyadic’s proprietary microbial platforms are poised to enhance the efficiency and sustainability of protein production across multiple sectors, positioning the company favorably for future commercialization opportunities.
Start your 7-day trial and see what the database can do →
